Chloroquine Exerts an Additive in Vitro Anti-HIV Type 1 Effect When Associated with Didanosine and Hydroxyurea

1999 ◽  
Vol 15 (14) ◽  
pp. 1241-1247 ◽  
Author(s):  
Johan R. Boelaert ◽  
Kirk Sperber ◽  
Jacques Piette
Keyword(s):  
Hiv Type 1 ◽  
Anti Hiv

Low Anticoagulant Heparin Retains Anti-HIV Type 1 Activity in Vitro

1995 ◽  
Vol 11 (11) ◽  
pp. 1393-1396 ◽  
Author(s):  
DEIRDRE R. COOMBE ◽  
HILARY A. HARROP ◽  
JANE WATTON ◽  
BARBARA MULLOY ◽  
TREVOR W. BARROWCLIFFE ◽  
...  
Keyword(s):  
Hiv Type 1 ◽  
Anti Hiv

Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs)

2011 ◽  
Vol 90 (3) ◽  
pp. 200-204 ◽  
Author(s):  
Geoffrey Férir ◽  
Kurt Vermeire ◽  
Dana Huskens ◽  
Jan Balzarini ◽  
Els J.M. Van Damme ◽  
...  
Keyword(s):  
Carbohydrate Binding ◽  
Binding Agents ◽  
Hiv Type 1 ◽  
Anti Hiv

scholarly journals Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Ramadan A. Mahmoud ◽  
Abdel-Azeem M. El-Mazary ◽  
Ashraf Khodeary
Keyword(s):  
Hepatitis C ◽  
Blood Transfusion ◽  
Hepatitis B ◽  
Thalassemia Major ◽  
Upper Egypt ◽  
Egyptian Children ◽  
Hiv Type 1 ◽  
Anti Hiv

Background. Frequent blood transfusions in thalassemia major children expose them to the risk of transfusion-transmitted infections (TTIs). The aim of this study was to estimate the prevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and cytomegalovirus (CMV) in thalassemic children attending the Pediatrics Departments of both Sohag and Minia Universities of Upper Egypt, during the period from May 2014 to May 2015.Methods. Serum samples were screened for hepatitis B surface antigen (HBsAg), anti-HCV, anti-CMV, and anti-HIV type 1 and type 2 using the Vitek Immunodiagnostic Assay System.Results. The frequencies of anti-HCV, HBsAg, anti-CMV, and anti-HIV type 1 and type 2 were found to be 37.11%, 4.12%, 4.12%, 0.00%, and 0.00%, respectively. Seropositivity for anti-HCV, HBsAg, and anti-CMV increased with increasing age of the patients, duration of the disease, serum ferritin level (ng/mL), and liver enzymes (U/L), while it was not significantly associated with gender, frequency of blood transfusion, or the status of splenectomy operation (P>0.05).Conclusion. The frequency of TTIs, especially HCV, is considerably high among Egyptian children with thalassemia major. It is therefore important to implement measures to improve blood transfusion screening, such as polymerase chain reaction, in order to reduce TTIs from blood donor units.

In Vitro HIV Type-1 Reverse Transcriptase Inhibitory Activity from Leaf Extracts ofScoparia dulcisL.

2009 ◽  
Vol 15 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Mahendar Porika ◽  
Mahender Aileni ◽  
Venugopal Rao Kokkirala ◽  
Kranthi Gadidasu ◽  
Pavan Umate ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Inhibitory Activity ◽  
Leaf Extracts ◽  
Hiv Type 1

The Design, Production, and Validation of an Anti-HIV Type 1 Ribozyme

2003 ◽  
pp. 51-64
Author(s):  
Lun-Quan Sun ◽  
Wayne Gerlach ◽  
Geoff Symonds
Keyword(s):  
Design Production ◽  
Hiv Type 1 ◽  
Anti Hiv

scholarly journals Mechanism of Action and In Vitro Activity of 1′,3′-Dioxolanylpurine Nucleoside Analogues against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants

1999 ◽  
Vol 43 (10) ◽  
pp. 2376-2382 ◽  
Author(s):  
Zhengxian Gu ◽  
Mark A. Wainberg ◽  
Nghe Nguyen-Ba ◽  
Lucille L’Heureux ◽  
Jean-Marc de Muys ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Mononuclear Cells ◽  
Nucleoside Analogues ◽  
Drug Resistant ◽  
Immunodeficiency Virus ◽  
Blood Mononuclear Cells ◽  
Anti Hiv ◽  
Hiv 1

ABSTRACT (−)-β-d-1′,3′-Dioxolane guanosine (DXG) and 2,6-diaminopurine (DAPD) dioxolanyl nucleoside analogues have been reported to be potent inhibitors of human immunodeficiency virus type 1 (HIV-1). We have recently conducted experiments to more fully characterize their in vitro anti-HIV-1 profiles. Antiviral assays performed in cell culture systems determined that DXG had 50% effective concentrations of 0.046 and 0.085 μM when evaluated against HIV-1IIIB in cord blood mononuclear cells and MT-2 cells, respectively. These values indicate that DXG is approximately equipotent to 2′,3′-dideoxy-3′-thiacytidine (3TC) but 5- to 10-fold less potent than 3′-azido-2′,3′-dideoxythymidine (AZT) in the two cell systems tested. At the same time, DAPD was approximately 5- to 20-fold less active than DXG in the anti-HIV-1 assays. When recombinant or clinical variants of HIV-1 were used to assess the efficacy of the purine nucleoside analogues against drug-resistant HIV-1, it was observed that AZT-resistant virus remained sensitive to DXG and DAPD. Virus harboring a mutation(s) which conferred decreased sensitivity to 3TC, 2′,3′-dideoxyinosine, and 2′,3′-dideoxycytidine, such as a 65R, 74V, or 184V mutation in the viral reverse transcriptase (RT), exhibited a two- to fivefold-decreased susceptibility to DXG or DAPD. When nonnucleoside RT inhibitor-resistant and protease inhibitor-resistant viruses were tested, no change in virus sensitivity to DXG or DAPD was observed. In vitro drug combination assays indicated that DXG had synergistic antiviral effects when used in combination with AZT, 3TC, or nevirapine. In cellular toxicity analyses, DXG and DAPD had 50% cytotoxic concentrations of greater than 500 μM when tested in peripheral blood mononuclear cells and a variety of human tumor and normal cell lines. The triphosphate form of DXG competed with the natural nucleotide substrates and acted as a chain terminator of the nascent DNA. These data suggest that DXG triphosphate may be the active intracellular metabolite, consistent with the mechanism by which other nucleoside analogues inhibit HIV-1 replication. Our results suggest that the use of DXG and DAPD as therapeutic agents for HIV-1 infection should be explored.

Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins

1997 ◽  
Vol 13 (8) ◽  
pp. 647-656 ◽  
Author(s):  
AN LI ◽  
TIMOTHY W. BABA ◽  
JOSEPH SODROSKI ◽  
SUSAN ZOLLA-PAZNER ◽  
MIROSLAW K. GORNY ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Hiv Type 1 ◽  
Anti Hiv

An Approach towards the Synthesis of Potential Metal-Chelating TSAO-T Derivatives as Bidentate Inhibitors of Human Immunodeficiency virus Type 1 Reverse Transcriptase

1998 ◽  
Vol 9 (5) ◽  
pp. 412-421 ◽  
Author(s):  
C Chamorro ◽  
M-J Camarasa ◽  
M-J Pérez-Pérez ◽  
E de Clercq ◽  
J Balzarini ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Reverse Transcriptase ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Parent Compound ◽  
Immunodeficiency Virus ◽  
Anti Hiv ◽  
Hiv 1

Novel derivatives of the potent human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitor TSAO-T have been designed, synthesized and tested for their in vitro antiretro-viral activity against HIV. These TSAO-T derivatives have been designed as potential bidentate inhibitors of HIV-1 RT, which combine in their structure the functionality of a non-nucleoside RT inhibitor (TSAO-T) and a bivalent ion-chelating moiety (a β-diketone moiety) linked through an appropriate spacer to the N-3 of thymine of TSAO-T . Some of the new compounds have an anti-HIV-1 activity comparable to that of the parent compound TSAO-T, but display a markedly increased antiviral selectivity. There was a clear relationship between antiviral activity and the length of the spacer group that links the TSAO molecule with the chelating moiety. A shorter spacer invariably resulted in increased antiviral potency. None of the TSAO-T derivatives were endowed with anti-HIV-2 activity.

HIV Type 2 Primary Isolates Induce a Lower Degree of Apoptosis "in Vitro" Compared with HIV Type 1 Primary Isolates

2004 ◽  
Vol 20 (5) ◽  
pp. 507-512 ◽  
Author(s):  
Ana Machuca ◽  
Linna Ding ◽  
Rolf Taffs ◽  
Sherwin Lee ◽  
Owen Wood ◽  
...  
Keyword(s):  
Lower Degree ◽  
Hiv Type 1
Sign in / Sign up

Export Citation Format

Share Document